Stocks and Investing Stocks and Investing
Wed, February 14, 2024

Andrew Fein Reiterated (BIIB) at Strong Buy and Held Target at $325 on, Feb 14th, 2024


Published on 2024-10-28 08:57:27 - WOPRAI, Andrew Fein
  Print publication without navigation


Andrew Fein of HC Wainwright & Co., Reiterated "Biogen Inc." (BIIB) at Strong Buy and Held Target at $325 on, Feb 14th, 2024.

Andrew has made no other calls on BIIB in the last 4 months.



There are 6 other peers that have a rating on BIIB. Out of the 6 peers that are also analyzing BIIB, 2 agree with Andrew's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Colin Bristow of "UBS" Downgraded from Strong Buy to Hold and Decreased Target to $276 on, Thursday, January 25th, 2024
  • Laura Chico of "Wedbush" Maintained at Hold with Decreased Target to $239 on, Thursday, November 9th, 2023


These are the ratings of the 4 analyists that currently disagree with Andrew


  • Eric Schmidt of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $311 on, Wednesday, December 20th, 2023
  • Paul Matteis of "Stifel" Maintained at Strong Buy with Decreased Target to $287 on, Thursday, December 14th, 2023
  • Danielle Brill of "Raymond James" Upgraded from Hold to Buy and Held Target at $283 on, Thursday, December 7th, 2023
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $373 on, Friday, November 10th, 2023

Contributing Sources